CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties. It has been shown to act as a potent, selective and irreversible inhibitor of the CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Reported to display a ~20-fold greater selectivity for CDC25 phosphatases over CD45 tyrosine phosphatase. Also shown to delay cell cycle progression in vitro (IC50 = ~7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cells MIA PaCa-2 (15 mg/kg, i.p. route).
1. Brezak, Marie-Christine., et al., 2004. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer research. 64(9): 3320-5. PMID: 15126376
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.